Navigation Links
Plasminogen activator inhibitor type-1 -- a potential link between heart failure and diabetes
Date:2/23/2009

Researchers at the University of Vermont Cardiovascular Research Institute, Colchester, Vermont have found that increased expression in the heart of plasminogen activator inhibitor type-1 (PAI-1) is profibrotic. The results, which appear in the March 2009 issue of Experimental Biology and Medicine, implicate PAI-1 overexpression, known to accompany insulin resistance and type 2 diabetes, as a factor contributing to the high incidence of heart failure after myocardial infarction in people with diabetes. The research team, Dr. A.K.M. Tarikuz Zaman, a research associate, Mr. Christopher J. French, medical and graduate student, Dr. David J. Schneider, Professor of Medicine and Director of the Cardiology and Vascular Biology Units, and Dr. Burton E. Sobel, Professor of Medicine and Director of the Cardiovascular Research Institute, performed studies in 10 week old mice subjected to coronary occlusion. Controls and PAI-1 overexpressing mice congenic on a C57BL6 background had comparable PAI-1 content in left ventricular myocardium despite a marked elevation of PAI-1 in plasma in the latter. 6 weeks after coronary occlusion the PAI-1 overexpressing mice exhibited a 2-fold increase in left ventricular (LV) PAI-1 content. Histochemical analysis demonstrated 33% more LV fibrosis as well. The increased fibrosis associated with increased PAI-1 was accompanied by functional derangements including diminished LV wall thickness in both diastole and systole, increased end systolic LV dimensions, depressed fractional shortening, a greater impairment of LV segmental function, and greater transmitral E-wave amplitude.

In summary, overexpression of PAI-1 in the heart altered the response of the left ventricle to myocardial infarction. It led to increased expression of PAI-1 late after coronary occlusion accompanied by increased fibrosis and functional derangements indicative of both systolic and diastolic dysfunction. Dr. Sobel said that "in concert with our previously reported findings demonstrating increased expression of PAI-1 in the heart in transgenic mice rendered insulin resistant, these results suggest that the markedly increased incidence and severity of heart failure following myocardial infarction in patients with insulin resistance and type 2 diabetes may reflect in part adverse consequences of increased PAI-1 expression in the heart predisposing to fibrosis and impairment performance of the left ventricle."

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine said "these elegant studies by Dr. Sobel and colleagues provide substantial insight into the mechanisms by which type 2 diabetes, with the resulting increase in PAI-1 in the heart, can lead to increased incidence and severity of heart failure following myocardial infarction. This is a major step forward in our understanding of the linkage between diabetes and cardiovascular disease".


'/>"/>

Contact: Dr. Burton Sobel
burton.sobel@uvm.edu
802-656-8955
Society for Experimental Biology and Medicine
Source:Eurekalert

Related biology news :

1. Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging
2. New inhibitor has potential as cancer drug
3. New research shows no link between aromatase inhibitors and cardiovascular problems
4. New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers
5. Scientists identify novel inhibitor of human microRNA
6. Researchers describe protease inhibitor that may aid in diabetic retinopathy treatment
7. Pittsburgh scientists identify human source of stem cells with potential to repair muscle
8. Neuronal conduction of excitation without action potentials based on ceramide production
9. To maximize biofuel potential, researchers look for sorghums sweet spot
10. Joslin researchers uncover potential role of leptin in diabetes
11. Chemistry turns killer gas into potential cure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2016)... -- SuperCom (NASDAQ:   SPCB ... Public Safety, HealthCare, and Finance sectors announced today that Leaders in ... implement and deploy a community-based supportive services program to reduce recidivism ... further expanding its presence in the state. ... This new program, which is expected to ...
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL ... desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar ... 2017, con múltiples sitios previstos a lo largo de Europa y ... MSC-1 es ... inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ...
(Date:12/16/2016)... The global wearable medical device market, in terms of value, is ... billion in 2016, at a CAGR of 18.0% during the forecast ... Growth ... devices, launch of a growing number of smartphone-based healthcare apps compatible ... and increasing focus on physical fitness. Furthermore, growing ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... -- Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. ... and inoperable solid tumor cancers, announced today that Dr. ... Bio, will present at the Phacilitate Immunotherapy World Conference ... Hotel in Miami, Florida . ... Therapeutic Approaches – Expanding the Reach of Cancer Immunotherapy ...
(Date:1/18/2017)... ... 18, 2017 , ... Opal Kelly, a leading producer of ... announced the ZEM5310 USB 3.0 FPGA Module, combining a SuperSpeed USB 3.0 interface ... factor suitable for prototyping, testing, and production-ready integration. The ZEM5310 USB interface delivers ...
(Date:1/18/2017)... Mass. , Jan. 18, 2017 ... applying mechanistic modeling to drug research and development, ... PhD, Co-Founder, President, and CEO of Applied BioMath, ... for Informatics and Modeling (BAGIM) Meeting on Thursday ... Cambridge , MA.   Dr. Burke,s ...
(Date:1/18/2017)... ... January 18, 2017 , ... Total ... successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took place on Wednesday, January 11, ... The procedure was an anterior cervical discectomy and fusion on a 42 year ...
Breaking Biology Technology: